Compare ADMA Biologics Inc (ADMA) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Live Nation Entertainment, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $43.01B). The key difference: Live Nation Entertainment, Inc. is far larger — about 19.7× ADMA Biologics Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | LYV | |
|---|---|---|
Market Cap | $2.18B | $43.01B |
Sector | Health | Industrials |
52-Week High | $20.38 | $186.59 |
52-Week Low | $7.60 | $125.61 |
Enterprise Value | $2.25B | $45.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Live Nation (LYV) trades at $180.66, down 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $209.54. The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by strong concert demand. However, valuation metrics like a P/E of 117.49 and a P/B of 511.19 appear elevated, while net income margin remains thin at 0.51% for 2025.
The outlook is supported by robust fan attendance and raised full-year expectations, but risks include high debt levels, legal uncertainties, and cost pressures. With 87% of analysts rating it a buy, the stock offers growth potential contingent on execution amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
